Increasing Attention to Prostate Cancer

Publication
Article
OncologyONCOLOGY Vol 15 No 4
Volume 15
Issue 4

A new bill called the Men’s Health Act of 2001 aims to focus more attention on diagnosing and treating men with prostate cancer. Rep. Randy Cunningham’s (R-Calif) Men’s Health

A new bill called the Men’s Health Act of 2001 aims to focusmoreattention on diagnosing and treating men with prostate cancer.Rep. Randy Cunningham’s (R-Calif) Men’s Health Act of 2001 doesn’texplicitly require that anything be done; it simply would establish an Office ofMen’s Health within the Public Health Service. (There is already a Women’sHealth Office.) 

The intentions of the bill (H.R. 632) are made clear byreferences to prostate cancer and, to a lesser extent, testicular cancer—theonly two diseases mentioned with emphasis. The Men’s Health Office would haveto send recommendations to Congress within 2 years of its establishment.

Recent Videos
Ablative technology may generate an immune response that can be enhanced via injected immunotherapy in patients with solid tumors.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Related Content